Following on from last week’s trading update indicating 100% plus revenue growth for the year to December 2015, the current financial year has got off to a flying start with the announcement of €3.4m of contracts with a leading US based Biotechnology client. These contracts are extensions of an existing Phase II programme. The work will commence immediately and run until the end of 2017 in multiple US and European sites.
12 Jan 2016
€3.4m of new contracts with US Biotech to commence immediately.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
€3.4m of new contracts with US Biotech to commence immediately.
hVIVO plc (HVO:LON) | 26.5 -0.1 (-2.0%) | Mkt Cap: 180.3m
- Published:
12 Jan 2016 -
Author:
Derren Nathan -
Pages:
6
Following on from last week’s trading update indicating 100% plus revenue growth for the year to December 2015, the current financial year has got off to a flying start with the announcement of €3.4m of contracts with a leading US based Biotechnology client. These contracts are extensions of an existing Phase II programme. The work will commence immediately and run until the end of 2017 in multiple US and European sites.